Related Experiment Video
Updated: May 10, 2026
15:05
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.6K
Structural Impact Assessment of Cytochrome P450 2A13 Polymorphisms Using Molecular Dynamics Simulations
Koichi Kato1,2, Tomoki Nakayoshi1,3, Sho Hioki1
1Faculty of Pharmacy, Meijo University.
Biological & Pharmaceutical Bulletin
|March 13, 2024
Summary
Genetic variations in CYP2A13 enzymes reduce their activity by altering structures. Molecular dynamics simulations revealed these changes impact heme interaction and helix stability, explaining decreased function in CYP2A13 variants.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Biology
Background:
- Cytochrome P450 (CYP) enzymes, specifically CYP2A13, are crucial for metabolizing various compounds including nicotine and tobacco-specific nitrosamines.
- Genetic polymorphisms in CYP2A13 are associated with reduced or lost enzymatic activity, impacting drug and carcinogen metabolism.
- Understanding the structural basis of these activity changes is vital for predicting individual metabolic responses.
Purpose of the Study:
- To elucidate the molecular mechanisms behind the diminished enzymatic activity observed in CYP2A13 allelic variants.
- To investigate the three-dimensional structural alterations in CYP2A13 variants using molecular dynamics simulations.
Main Methods:
- Performed 1000 ns molecular dynamics (MD) simulations for multiple CYP2A13 variants and compared them to the wild type.
- Analyzed conformational changes, focusing on interactions with heme and redox partners.
Main Results:
- MD simulations revealed significant alterations in heme interaction for CYP2A13 variants .4, .6, .8, and .9.
- CYP2A13 variant .5 showed notable changes in helix structure affecting redox partner interaction.
- These structural modifications were directly correlated with decreased enzyme activity in the studied variants.
Conclusions:
- The study provides a molecular-level understanding of how CYP2A13 polymorphisms lead to reduced enzyme function.
- Identified structural changes in heme binding and helix stability are key determinants of decreased CYP2A13 activity.
- These findings contribute to predicting the functional consequences of CYP2A13 genetic variations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...